SK Biopharmaceuticals bags XCOPRI FDA approval for partial-onset seizures

SK Biopharmaceuticals bags XCOPRI FDA approval for partial-onset seizures

XCOPRI FDA approval : SK Biopharmaceuticals said that its US subsidiary SK Life Science has been granted approval from the US Food and Drug Administration (FDA) for its anti-epileptic drug XCOPRI (cenobamate tablets) for the treatment for partial-onset seizures in adults. According to the FDA, a seizure is normally a short episode of abnormal electrical activity […]

Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome

Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome

US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate – STK-001 from the US Food and Drug Administration (FDA) for the treatment for Dravet syndrome. Considered to be a severe and progressive genetic epilepsy, Dravet syndrome is characterized by frequent, prolonged and refractory seizures that start within the first […]

Martindale Pharma’s Epaclob and Silocalm gain regulatory approval in seven European countries

Martindale Pharma’s Epaclob and Silocalm gain regulatory approval in seven European countries

Martindale Pharma, a UK-based global pharmaceutical company, has successfully secured regulatory approval for its innovative clobazam oral suspension, branded as Epaclob and Silocalm, in seven European countries. This marks a significant expansion of the company’s product availability across the continent. Broad Regulatory Approval The regulatory approval encompasses France, Ireland, Germany, and Italy for Epaclob, and […]